Bridging the Digital Divide: Real-World Efficacy of Commercial and Open-Source Automated Insulin Delivery Systems in a Diverse, Low-Resource Pediatric Population

BACKGROUND: Achieving optimal glycemic control in type 1 diabetes (T1D) is challenging. Automated insulin delivery (AID) systems have improved outcomes, yet data on open-source systems-particularly in low-resource, low technological literacy settings-remain limited. This study compared the efficacy and safety of an open-source system with a regulatory-approved system in a heterogeneous real-world pediatric cohort. METHODS: This longitudinal observational study included 61 children with T1D treated at Shaare Zedek Medical Center: 30 using the regulatory-approved Medtronic 780G and 31 using the open-source AndroidAPS AID system. Socioeconomic status (SES) was determined by residential address. Glycemic outcomes were compared between AID use and prior sensor-augmented pump therapy. Primary endpoints included changes in time in range (TIR), average glucose, glucose management indicator (GMI), and hypoglycemia/hyperglycemia duration. Safety outcomes included rates of severe hypoglycemia and diabetic ketoacidosis (DKA). RESULTS: Both groups demonstrated significant glycemic improvements after transitioning to AID, including an increase in %TIR (56.6 ± 14.1 vs 69.3 ± 8.8) and reduction in average blood glucose (173.3 ± 31.7 vs 149.9 ± 18.3), GMI and % time in hyperglycemia. No significant differences in glycemic outcomes were observed between groups, although a trend toward greater reduction in average blood glucose and GMI was observed in the regulatory-approved group. No episodes of severe hypoglycemia or DKA occurred in either group. CONCLUSIONS: In a heterogeneous real-world pediatric cohort including a low-resource population with limited technological access, both AID systems significantly improved glycemic outcomes without compromising safety. These findings suggest AID benefits transcend socioeconomic barriers, supporting patient autonomy in system selection.

Authors

Institutions

Publication Details

Journal
Journal of Diabetes Science and Technology
Published
2026-08-25
DOI
https://doi.org/10.1177/19322968261477764
Primary Topic
Diabetes Management and Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Bridging the Digital Divide: Real-World Efficacy of Commercial and Open-Source Automated Insulin Delivery Systems in a Diverse, Low-Resource Pediatric Population

Floris Levy‐Khademi, Adi Auerbach, Carmit Avnon-Ziv, Karin Dreifuss
Journal of Diabetes Science and Technology
Diabetes Management and Research
article

Bridging the Digital Divide: Real-World Efficacy of Commercial and Open-Source Automated Insulin Delivery Systems in a Diverse, Low-Resource Pediatric Population

Floris Levy‐Khademi, Adi Auerbach, Carmit Avnon-Ziv, Karin Dreifuss
article en

Abstract

BACKGROUND: Achieving optimal glycemic control in type 1 diabetes (T1D) is challenging. Automated insulin delivery (AID) systems have improved outcomes, yet data on open-source systems-particularly in low-resource, low technological literacy settings-remain limited. This study compared the efficacy and safety of an open-source system with a regulatory-approved system in a heterogeneous real-world pediatric cohort. METHODS: This longitudinal observational study included 61 children with T1D treated at Shaare Zedek Medical Center: 30 using the regulatory-approved Medtronic 780G and 31 using the open-source AndroidAPS AID system. Socioeconomic status (SES) was determined by residential address. Glycemic outcomes were compared between AID use and prior sensor-augmented pump therapy. Primary endpoints included changes in time in range (TIR), average glucose, glucose management indicator (GMI), and hypoglycemia/hyperglycemia duration. Safety outcomes included rates of severe hypoglycemia and diabetic ketoacidosis (DKA). RESULTS: Both groups demonstrated significant glycemic improvements after transitioning to AID, including an increase in %TIR (56.6 ± 14.1 vs 69.3 ± 8.8) and reduction in average blood glucose (173.3 ± 31.7 vs 149.9 ± 18.3), GMI and % time in hyperglycemia. No significant differences in glycemic outcomes were observed between groups, although a trend toward greater reduction in average blood glucose and GMI was observed in the regulatory-approved group. No episodes of severe hypoglycemia or DKA occurred in either group. CONCLUSIONS: In a heterogeneous real-world pediatric cohort including a low-resource population with limited technological access, both AID systems significantly improved glycemic outcomes without compromising safety. These findings suggest AID benefits transcend socioeconomic barriers, supporting patient autonomy in system selection.

Journal of Diabetes Science and Technology
Hebrew University of Jerusalem (IL), Shaare Zedek Medical Center (IL)
Quality Education
Openalex Percentile: Top 10%
Diabetes Management and Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.